Hepatitis Therapeutics - Global Market Size, Share and Trend Analysis to 2025 - Key Players are Gilead, Johnson & Johnson, Merck, Bristol-Myers Squibb and AbbVie - ResearchAndMarkets.com

November 7, 2018

DUBLIN--(BUSINESS WIRE)--Nov 7, 2018--The “Hepatitis Therapeutics Market Size, Share, And Trend Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 - 2025” report has been added to ResearchAndMarkets.com’s offering.

The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025.A few factors that are expected to drive the market over the forecast period include rising number of hepatitis infected population, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs.Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally and annually nearly 1.4 people die due to the condition. In order to prevent hepatitis, few government and private agencies are actively involved in the vaccination drive to prevent hepatitis.As compared to hepatitis A and B, HCV leads to more serious complications. According to the estimates of WHO, globally annually 150 million are impacted by hepatitis C infection. Moreover, majority of HCV infected patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Key Findings

Owing to high prevalence of target disease with subsequently surge in treatment rate HCV, thus hepatitis C therapeutics held the majority market share in 2016In 2016, North American region accounted for majority of revenue share of 42.9% owing to high patient awareness levels and the presence of advanced healthcare infrastructureHowever, Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period owing to rapidly increasing healthcare expenditureKey players include Gilead, Johnson & Johnson, Merck & Co. Inc., Bristol-Myers Squibb Company and AbbVie Inc.

Topics Covered

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Hepatitis Therapeutics Market Variables, Trends & Scope

Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis

Chapter 5. Hepatitis Therapeutics Market: Regional Outlook, By Disease Type

Chapter 6. Competitive Landscape

Gilead LifesciencesBristol-Myers Squibb Co.BioconAbbVieMerck & Co. Inc.Johnson & Johnson

For more information about this report visit https://www.researchandmarkets.com/research/4g9wv7/hepatitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181107005482/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/07/2018 07:53 AM/DISC: 11/07/2018 09:34 AM


Update hourly